Clinigen Group’s (CLIN) “Buy” Rating Reaffirmed at Peel Hunt
Several other brokerages have also weighed in on CLIN. UBS Group restated a buy rating and issued a GBX 1,160 ($15.16) price objective on shares of Clinigen Group in a report on Thursday, September 27th. Numis Securities restated a buy rating and issued a GBX 1,275 ($16.66) price objective on shares of Clinigen Group in a report on Monday, October 8th. Finally, Royal Bank of Canada restated a top pick rating and issued a GBX 1,470 ($19.21) price objective (up previously from GBX 1,360 ($17.77)) on shares of Clinigen Group in a report on Monday, October 15th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of GBX 1,265 ($16.53).
Shares of CLIN stock opened at GBX 812 ($10.61) on Thursday. Clinigen Group has a 1 year low of GBX 751.50 ($9.82) and a 1 year high of GBX 1,187 ($15.51).
Clinigen Group Company Profile
Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.
Featured Story: How to Invest in Marijuana Stocks
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.